Inari Medical (NARI) reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.
Analysts polled by Capital IQ expected a $0.18 loss.
Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.
Analysts surveyed by Capital IQ expected $150.7 million.
In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.
Analysts project $600 million.
Inari said it continues to expect to reach sustained operating profitability in H1.
The company's shares rose 10% in after-hours activity.
Price: 47.00, Change: +4.44, Percent Change: +10.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。